Globus Medical/$GMED
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Globus Medical
Through innovative technology and M&A activity, Globus Medical transformed into the number two medical device manufacturer in the competitive spine market. The firm was founded in 2003 with a heavy focus on internal research and development but vaulted its market share in 2023 through a merger with former competitor NuVasive. In 2025, the company acquired Nevro, a smaller player that specialized in spinal cord stimulation therapy. Globus Medical reports two business segments, musculoskeletal solutions and enabling technologies, which consist of implants used in surgery and associated technologies that assist the physician.
- Ticker
- $GMED
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 6,000
- Headquarters
- Audubon, United States
- Website
- www.globusmedical.com
Globus Medical Metrics
BasicAdvanced
$9.6B
17.81
$4.06
0.95
-
Price and volume
Market cap
$9.6B
Beta
0.95
52-week high
$101.40
52-week low
$70.40
Average daily volume
1.9M
Financial strength
Current ratio
4.296
Quick ratio
2.444
Long term debt to equity
0.02
Total debt to equity
0.023
Profitability
EBITDA (TTM)
1,025.292
Gross margin (TTM)
69.33%
Net profit margin (TTM)
17.76%
Operating margin (TTM)
23.76%
Effective tax rate (TTM)
20.27%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
8.78%
Return on equity (TTM)
12.13%
Valuation
Price to earnings (TTM)
17.807
Price to revenue (TTM)
3.103
Price to book
2
Price to tangible book (TTM)
3.59
Price to free cash flow (TTM)
12.872
Free cash flow yield (TTM)
7.77%
Free cash flow per share (TTM)
5.617
Growth
Revenue change (TTM)
13.35%
Earnings per share change (TTM)
31.85%
3-year revenue growth (CAGR)
36.80%
10-year revenue growth (CAGR)
18.97%
3-year earnings per share growth (CAGR)
40.48%
10-year earnings per share growth (CAGR)
12.78%
What the Analysts think about Globus Medical
Analyst ratings (Buy, Hold, Sell) for Globus Medical stock.
Analyst projections of the future price of Globus Medical stock.
Bulls say / Bears say
Adjusted gross margin rose 140 basis points to 69.5%, and Globus kept its 2026 adjusted EPS outlook at $4.95–$5.05, implying growth of 24.4%–26.9%. Sustained margin gains could support earnings growth despite softer sales. (Globus Medical)
The company generated a record $224.8 million in quarterly free cash flow and authorised a further $500 million for share repurchases. Strong cash generation gives it scope to return capital while funding its business. (The Motley Fool)
Enabling Technologies revenue grew 24%, while robot and navigation deployments rose 73% year on year. Wider adoption could expand the installed base and create more opportunities to sell related products and services. (Globus Medical)
Third-quarter sales fell 0.7% year on year, and Globus cut its 2026 revenue outlook to $3.09 billion from $3.18–$3.22 billion. The reset points to weaker near-term growth than previously expected. (Globus Medical)
Nevro revenue fell 25.7% to $73.7 million, with weak trial volumes delaying its recovery. Continued declines could weigh on group sales and undermine the expected benefit from the acquisition. (The Motley Fool)
U.S. Spine grew just 2% as product launches were delayed, production issues lingered and competitive recruiting contributed less than expected. Management said the delayed launches would have little effect on 2026 sales, leaving more of the recovery case dependent on 2027 execution. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.
Globus Medical Financial Performance
Revenues and expenses
Globus Medical Earnings Performance
Company profitability
Upcoming events
No upcoming events
Globus Medical News
AllArticlesVideos
Funds containing Globus Medical
Fund name | Fund size | $GMED weighting |
|---|---|---|
L&G ROBO Global Robotics and Automation$ROBO | $1.7B | 1.36% |
L&G ROBO Global Robotics and Automation£ROBG | $1.7B | 1.36% |
iShares Ageing Population€AGED | $887M | 0.44% |
iShares Ageing Population£AGES | $887M | 0.44% |
iShares Ageing Population$AGED | $887M | 0.44% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.